2.53
-0.17 (-6.43%)
| Penutupan Terdahulu | 2.70 |
| Buka | 2.61 |
| Jumlah Dagangan | 77,346 |
| Purata Dagangan (3B) | 159,706 |
| Modal Pasaran | 40,607,312 |
| Harga / Jualan (P/S) | 3.11 |
| Harga / Buku (P/B) | 2.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Feb 2026 |
| Margin Keuntungan | -215.24% |
| Margin Operasi (TTM) | -242.68% |
| EPS Cair (TTM) | -0.220 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.10% |
| Nisbah Semasa (MRQ) | 3.80 |
| Aliran Tunai Operasi (OCF TTM) | -29.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.41 M |
| Pulangan Atas Aset (ROA TTM) | -49.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -93.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Veru Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.88 |
|
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.19% |
| % Dimiliki oleh Institusi | 33.43% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sheets Smith Investment Management | 30 Sep 2025 | 322,084 |
| Pvg Asset Management Corp | 30 Sep 2025 | 158,810 |
| Julat 52 Minggu | ||
| Median | 25.00 (888.14%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 18 Dec 2025 | 25.00 (888.14%) | Beli | 2.26 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th |
| 17 Dec 2025 | Pengumuman | Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress |
| 10 Dec 2025 | Pengumuman | Veru to Report Fiscal Year 2025 Financial Results on December 17th |
| 04 Dec 2025 | Pengumuman | Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop |
| Purata Hasil Dividen 5T | 0.00% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 28 Apr 2014 | 24 Mar 2014 | 07 May 2014 | 0.07 Tunai |
| 27 Jan 2014 | 16 Dec 2013 | 05 Feb 2014 | 0.07 Tunai |
| 28 Oct 2013 | 03 Oct 2013 | 06 Nov 2013 | 0.07 Tunai |
| 29 Jul 2013 | 15 Jul 2013 | 07 Aug 2013 | 0.07 Tunai |
| 28 Jan 2013 | 03 Jan 2013 | 06 Feb 2013 | 0.06 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2014 | 0.140 | 2 | 0.36 |
| 2013 | 0.200 | 3 | 0.24 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |